Form 8-K - Current report:
SEC Accession No. 0000950170-24-123321
Filing Date
2024-11-07
Accepted
2024-11-07 16:10:09
Documents
13
Period of Report
2024-11-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kura-20241107.htm   iXBRL 8-K 46411
2 EX-99.1 kura-ex99_1.htm EX-99.1 128730
3 GRAPHIC img71811756_0.jpg GRAPHIC 6669
  Complete submission text file 0000950170-24-123321.txt   317284

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kura-20241107.xsd EX-101.SCH 30906
15 EXTRACTED XBRL INSTANCE DOCUMENT kura-20241107_htm.xml XML 4709
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37620 | Film No.: 241435717
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)